Certara Expands Presence in China and Taiwan

Certara, a translational sciences company formed by the acquisition of Pharsight by Tripos, announced expanded investment and presence in China and Taiwan in support of drug discovery and development efforts, and also confirmed that Tri-I Biotech has been selected as the sole distributor of the combined Certara offerings in the two countries.

"We are very pleased with the selection of Tri-I Biotech as our partner in the strategic markets of mainland China and Taiwan," said Patrick Flanagan, Chief Operating Officer for Certara. "Working with Tri-I, pharmaceutical and biotech drug discovery and development organizations will have easy access to Certara's tools, training and support. This will enable the research community to more effectively analyze, interpret, and share data and key information. Tri-I is an important part of the Certara service and support strategy, and they will provide drug discovery and development scientists within mainland China and Taiwan with full access to Certara's wide range of new software solutions, as well as new releases of existing products."

"By combining Tripos' and Pharsight's powerful product and service offerings, Certara is uniquely positioned to bridge the translational pharmacology market space, offering solutions that begin in drug discovery and span clinical trials," said Steve Hsu, President of Tri-I Biotech. "We are very pleased to be the partner of choice for Certara, and to help clients in mainland China and Taiwan propel their research efforts forward using these important technologies."

((Comments on this story may be sent to newsdesk@closeupmedia.com))

Related terms: biotechnology, china, clinical, community, distributor, investment, market, pharmaceuticals, president, products, research, taiwan, technology, training